Liraglutide (NN2211) is a long-acting gluca on-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxend as a treatment for obesity in adults with at least one weight-related comorbid condition.
| Product name | Liraglutide | |
| Appearance | white solid | |
| Purity | 99%min | |
| CAS No. | 204656-20-2 | |
| EINECS No. | 810-818-7 | |
| MF. | C172H265N43O51 | |
| Grade Standard | Medicine Grade | |
Application
Liraglutide has advantages over more traditional therapies for type 2 diabetes:
1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insu.lin secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Liraglutide lowers blood triglyceride levels.
For high value products, please select air shipping and express delivery for safety.
Company Profile:
Shandong Longilat Biotechnology Co., Ltd was established in 2015. It is a high-tech professional and technological enterprise integrating R & D, production, and sales.
Longilat 's main products are food additives, plant extracts, cosmetic raw materials, feed additives, animal extract, amino acids and vitamins. Most of our products are derived from natural plants. Marketing services are available in many countries around the world.
